ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

New Treatment Approach To Treating Brain Tumor

April 26, 2002

DCT To Announce Three New CRAGs

November 12, 1976

NCI Programs: Institute To Contact For Software To Control Ultrasound Imaging

November 19, 1999

Komen Foundation Awards New Grants

October 20, 1995

Sustained-Release Leuprolide Under Study In Phase III Trial.

June 30, 2000

Health Organizations: ACS Statement Supports funding of Research On Human Stem cells

December 17, 1999